Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic...
View Details
Keywords:
Global Strategy;
Health Pandemics;
Distribution;
Logistics;
Production;
Supply Chain Management;
Performance Capacity;
Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
- 08 Jan 2020
- Video
Dr. Yusuf Hamied
Dr. Yusuf Hamied, Chair of the pioneering Indian generic drugs company Cipla, explains his objection to the patent monopolies of Western multinational companies, to whom he believes India should not be at the...
View Details
- November 2019
- Article
Many Medicare Beneficiaries with Serious Illness Report Financial Hardships Despite Coverage
By: Michael Anne Kyle, Robert J Blendon, John M Benson, Melinda K Abrams and Eric C Schneider
In a national survey, seriously ill Medicare beneficiaries described financial hardships resulting from their illness—despite high beneficiary satisfaction with Medicare overall and the fact that many have supplemental insurance. About half reported a serious problem...
View Details
Kyle, Michael Anne, Robert J Blendon, John M Benson, Melinda K Abrams, and Eric C Schneider. "Many Medicare Beneficiaries with Serious Illness Report Financial Hardships Despite Coverage." Health Affairs 38, no. 11 (November 2019): 1801–1806.
- September 1999 (Revised September 2005)
- Case
Strategic Deal Making at Millennium Pharmaceuticals
A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug...
View Details
Keywords:
Alliances;
Negotiation Deal;
Growth and Development Strategy;
Pharmaceutical Industry;
Cambridge
Watkins, Michael D., and Sarah Matthews. "Strategic Deal Making at Millennium Pharmaceuticals." Harvard Business School Case 800-032, September 1999. (Revised September 2005.)
- 26 Jul 2016
- Working Paper Summaries
The Impact of the Entry of Biosimilars: Evidence from Europe
- 2021
- Working Paper
The Health Costs of Cost-Sharing
By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
We use the design of Medicare’s prescription drug benefit program to demonstrate three facts about the health consequences of cost-sharing. First, we show that an as-if-random increase of 33.6% in out-of-pocket price (11.0 percentage points (p.p.) change in...
View Details
Chandra, Amitabh, Evan Flack, and Ziad Obermeyer. "The Health Costs of Cost-Sharing." NBER Working Paper Series, No. 28439, February 2021.
- 01 Nov 2019
- News
Trump Bets on Washington Outsider to Lead FDA Amid Political Battles
- May 2017
- Article
When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization
By: Leemore S. Dafny, Christopher Ody and Matt Schmitt
Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry...
View Details
Dafny, Leemore S., Christopher Ody, and Matt Schmitt. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization." American Economic Journal: Economic Policy 9, no. 2 (May 2017): 91–123.
- November 2012
- Supplement
Amylin Pharmaceuticals (B)
By: Richard G. Hamermesh and Carin-Isabel Knoop
Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical...
View Details
Keywords:
Pharmaceuticals;
Bristol-Myers Squibb;
Health Care and Treatment;
Pharmaceutical Industry;
United States
Hamermesh, Richard G., and Carin-Isabel Knoop. "Amylin Pharmaceuticals (B)." Harvard Business School Supplement 813-091, November 2012.
When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization
Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost-sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry...
View Details
- 12 Nov 2019
- Video
Kiran Mazumdar Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, explains how her firm developed over four years a new technology for making insulin, an essential...
View Details
- 01 Nov 2013
- HBS Seminar
Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals
- January 2001
- Case
Merck Global Health Initiatives (A)
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,...
View Details
Keywords:
Programs;
Philanthropy and Charitable Giving;
Health Disorders;
Health Care and Treatment;
Private Sector;
Public Sector;
Alliances;
Problems and Challenges;
Pharmaceutical Industry;
Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (A)." Harvard Business School Case 301-088, January 2001.
- 20 Aug 2020
- Blog Post
Being patients compelled us. Sequoia inspired us. HBS sustained us.
marketing dollars (and influence) from clinics or drug companies. While in treatment, I was a very junior partner (pretty much sweeping the floors) at Sequoia Capital and I’d learned that small teams change the world. Take Instagram or...
View Details
- 28 Sep 2020
- Working Paper Summaries
What Can Economics Say About Alzheimer's Disease?
- 14 Jul 2023
- Video
BiGS Idea: Rethinking Health Equity
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- August 1995 (Revised June 1997)
- Case
Hillcrest Research Associates, Inc.
Hillcrest designs and administers testing procedures for drugs to determine whether they pass FDA specifications. As the company grows, it encounters problems with information technology and with the clinical research associates, who feel pressured to report more...
View Details
Keywords:
Growth Management;
Information Technology;
Health Testing and Trials;
Pharmaceutical Industry
Barnes, Louis B. "Hillcrest Research Associates, Inc." Harvard Business School Case 496-021, August 1995. (Revised June 1997.)
- 07 Jun 2023
- News
Martine Rothblatt: Making Implausible Dreams Reality
- June 1996 (Revised February 1998)
- Case
Repositioning Ranbaxy
A leading Indian pharmaceutical company reacts to changes in its industry by trying to reposition along several dimensions from developing markets to developed ones, from bulk drugs toward pharmaceuticals in dosage forms, and from reverse-engineering products developed...
View Details
Keywords:
Organizational Change and Adaptation;
Expansion;
Industry Structures;
Pharmaceutical Industry;
India
Ghemawat, Pankaj, and Kazbi Kothavala. "Repositioning Ranbaxy." Harvard Business School Case 796-181, June 1996. (Revised February 1998.)